Kensington Investment Counsel LLC Takes Position in TransMedics Group, Inc. $TMDX

Kensington Investment Counsel LLC purchased a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the 3rd quarter, Holdings Channel reports. The fund purchased 17,165 shares of the company’s stock, valued at approximately $1,926,000.

Several other hedge funds have also recently bought and sold shares of TMDX. Intech Investment Management LLC grew its stake in TransMedics Group by 28.9% during the 2nd quarter. Intech Investment Management LLC now owns 34,389 shares of the company’s stock valued at $4,608,000 after acquiring an additional 7,713 shares in the last quarter. Nordea Investment Management AB purchased a new stake in shares of TransMedics Group in the third quarter worth approximately $4,070,000. Peregrine Capital Management LLC boosted its holdings in shares of TransMedics Group by 16.5% during the third quarter. Peregrine Capital Management LLC now owns 68,406 shares of the company’s stock worth $7,675,000 after purchasing an additional 9,676 shares during the period. Intrust Bank NA acquired a new stake in shares of TransMedics Group during the second quarter worth approximately $747,000. Finally, Fieldview Capital Management LLC purchased a new position in TransMedics Group during the third quarter valued at approximately $1,716,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at TransMedics Group

In other news, insider Nicholas Corcoran sold 2,966 shares of the stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $139.12, for a total transaction of $412,629.92. Following the transaction, the insider owned 29,831 shares in the company, valued at $4,150,088.72. This represents a 9.04% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Stephanie Lovell sold 1,193 shares of the firm’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $149.62, for a total transaction of $178,496.66. Following the transaction, the director owned 2,866 shares in the company, valued at $428,810.92. This represents a 29.39% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 16,205 shares of company stock worth $2,353,002 over the last quarter. 7.00% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms have weighed in on TMDX. JPMorgan Chase & Co. upped their price objective on shares of TransMedics Group from $114.00 to $149.00 and gave the company a “neutral” rating in a research note on Wednesday, February 25th. Wall Street Zen cut shares of TransMedics Group from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Oppenheimer upped their price target on shares of TransMedics Group from $150.00 to $175.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Needham & Company LLC increased their price objective on TransMedics Group from $166.00 to $174.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Finally, Canaccord Genuity Group lifted their price objective on TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Seven equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $152.33.

TransMedics Group Price Performance

Shares of TMDX opened at $124.72 on Wednesday. The company has a debt-to-equity ratio of 1.06, a quick ratio of 6.59 and a current ratio of 7.14. The firm has a market cap of $4.28 billion, a PE ratio of 25.45 and a beta of 1.98. The firm’s 50 day moving average price is $135.73 and its 200 day moving average price is $127.46. TransMedics Group, Inc. has a twelve month low of $62.23 and a twelve month high of $156.00.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.